Skip to main content

Lynx Crosses Into Black for Q3

NEW YORK, Nov. 13 (GenomeWeb News) -Lynx Therapeutics today crossed into the black, reporting net income of $1.8 million for the third quarter of 2003.


"Our operating performance in the third quarter of 2003 reflects higher genomics revenues and continued aggressive management of our expenses," Kevin Corcoran, Lynx's President, said in a statement.


The Hayward, Calif., company's revenues came to $8.3 million for the third quarter, up from $4.8 million for the third quarter of last year.


R&D expenses decreased to $3.0 million, compared to $4.3 million for the same period last year.

As of Sept. 30, Lynx had $6.4 million in cash and cash equivalents, including restricted cash, compared to $11.7 million for the same period last year.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.